™ 780g advanced hybrid closed loop ahcl system Search Results


tm 780g ahcl system with guardian 4 tm sensor (g4s)  (MiniMed Inc)
90
MiniMed Inc tm 780g ahcl system with guardian 4 tm sensor (g4s)
Glycemic outcomes and system usability categorized by age groups after 3 months of use of an advanced hybrid closed-loop system compared to baseline (continuous subcutaneous insulin infusion and flash glucose monitoring).
Tm 780g Ahcl System With Guardian 4 Tm Sensor (G4s), supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+780g+advanced+hybrid+closed+loop+ahcl+system/minimed+780g/pmc10647771-38-77-76
Average 90 stars, based on 1 article reviews
tm 780g ahcl system with guardian 4 tm sensor (g4s) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
780g ahcl system  (Medtronic inc)
90
Medtronic inc 780g ahcl system
CONSORT flow diagram for the enrolled participants with type 1 diabetes and diabetic nephropathy on the MiniMed <t>780G</t> system
780g Ahcl System, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+780g+advanced+hybrid+closed+loop+ahcl+system/780g/pmc11604790-159-3-44
Average 90 stars, based on 1 article reviews
780g ahcl system - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Glycemic outcomes and system usability categorized by age groups after 3 months of use of an advanced hybrid closed-loop system compared to baseline (continuous subcutaneous insulin infusion and flash glucose monitoring).

Journal: Journal of Clinical Medicine

Article Title: Pediatric Type 1 Diabetes: Is Age at Onset a Determining Factor in Advanced Hybrid Closed-Loop Insulin Therapy?

doi: 10.3390/jcm12216951

Figure Lengend Snippet: Glycemic outcomes and system usability categorized by age groups after 3 months of use of an advanced hybrid closed-loop system compared to baseline (continuous subcutaneous insulin infusion and flash glucose monitoring).

Article Snippet: We included pediatric and adolescent patients aged 7 to 17 years, diagnosed with T1D according to the latest ADA and ISPAD criteria [ , ], who were on combined treatment with continuous subcutaneous insulin infusion (CSII) (MiniMed TM, Medtronic MiniMed, 18000 Devonshire Street, Northridge, CA 91325, USA) and intermittently scanned continuous glucose monitoring (isCGM) (FreeStyle Libre 2 ® Abbott Diabetes Care 1360 South Loop Road Alameda, CA 94502, USA) and had this system replaced with the MiniMed TM 780G AHCL system with Guardian 4 TM sensor (G4S) between December 2021 and April 2022.

Techniques:

CONSORT flow diagram for the enrolled participants with type 1 diabetes and diabetic nephropathy on the MiniMed 780G system

Journal: Diabetologia

Article Title: The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial

doi: 10.1007/s00125-024-06265-7

Figure Lengend Snippet: CONSORT flow diagram for the enrolled participants with type 1 diabetes and diabetic nephropathy on the MiniMed 780G system

Article Snippet: This study included type 1 diabetes 780G AHCL system users ( n =46; 21 male and 25 female participants) who had ≥14 days of SG data on AHCL with a Guardian 3 ( n =15) or Guardian 4 ( n =31) sensor supplied by Medtronic, Northridge, CA, USA.

Techniques:

MiniMed 780G system performance between sitagliptin and control groups at baseline and at study end among the enrolled participants with type 1 diabetes and diabetic nephropathy

Journal: Diabetologia

Article Title: The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial

doi: 10.1007/s00125-024-06265-7

Figure Lengend Snippet: MiniMed 780G system performance between sitagliptin and control groups at baseline and at study end among the enrolled participants with type 1 diabetes and diabetic nephropathy

Article Snippet: This study included type 1 diabetes 780G AHCL system users ( n =46; 21 male and 25 female participants) who had ≥14 days of SG data on AHCL with a Guardian 3 ( n =15) or Guardian 4 ( n =31) sensor supplied by Medtronic, Northridge, CA, USA.

Techniques: Control

Percentage change from baseline to study end between sitagliptin and control groups as regards MiniMed 780G glucometrics and glycaemic excursions among the enrolled participants with type 1 diabetes and diabetic nephropathy

Journal: Diabetologia

Article Title: The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial

doi: 10.1007/s00125-024-06265-7

Figure Lengend Snippet: Percentage change from baseline to study end between sitagliptin and control groups as regards MiniMed 780G glucometrics and glycaemic excursions among the enrolled participants with type 1 diabetes and diabetic nephropathy

Article Snippet: This study included type 1 diabetes 780G AHCL system users ( n =46; 21 male and 25 female participants) who had ≥14 days of SG data on AHCL with a Guardian 3 ( n =15) or Guardian 4 ( n =31) sensor supplied by Medtronic, Northridge, CA, USA.

Techniques: Control